The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics. The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).
What the Market Looks Like?
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%. The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics.
The high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market. In addition, the growth in the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.
Download PDF Brochure @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575
What are Key Trends in the Market?
The growth of the US anticoagulation therapy market is primarily influenced by the following factors:
- Rising Incidence of Venous Thromboembolism, Atrial Fibrillation, and Stroke
- Increasing Demand for Noacs as Alternatives to Warfarin
- Growing Number of Patients Requiring Lifelong Anticoagulation Therapy
Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs.
Read more about Anticoagulation Therapy Market@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575